Yin Yang 1 modulates taxane response in epithelial ovarian cancer

Molecular Cancer Research

Volumn 7, Issue 2, 2009, Pages 210-220

  Matsumura, Noriomi ^a,c   Huang, Zhiqing ^a   Baba, Tsukasa ^a,c   Lee, Paula S ^a   Barnett, Jason C ^a   Mori, Seiichi ^b   Chang, Jeffrey T ^b   Kuo, Wen Lin ^d   Gusberg, Alison H ^a   Whitaker, Regina S ^a   Gray, Joe W ^d   Fujii, Shingo ^c   Berchuck, Andrew ^a,b   Murphy, Susan K ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY   (United States)

^c KYOTO UNIVERSITY   (Japan)

^d LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; MESSENGER RNA; PACLITAXEL; PLATINUM DERIVATIVE; SMALL INTERFERING RNA; TAXANE DERIVATIVE; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR YY1;

ARTICLE; BIOLOGY; CANCER CELL CULTURE; CANCER PATIENT; CANCER SURVIVAL; CELL GROWTH; CELL MOTILITY; CELL PROLIFERATION; DATA BASE; DRUG EFFECT; DRUG RESPONSE; DRUG SENSITIVITY; EPIGENETICS; FEMALE; GENE CLUSTER; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROARRAY ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN MOTIF; TUMOR GENE; YIN YANG 1 GENE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BINDING SITES; CELL MOVEMENT; CELL PROLIFERATION; CISPLATIN; COMPARATIVE GENOMIC HYBRIDIZATION; E2F TRANSCRIPTION FACTORS; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOENZYME TECHNIQUES; NEOPLASMS, GLANDULAR AND EPITHELIAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PACLITAXEL; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SURVIVAL RATE; TAXOIDS; WOUND HEALING; YY1 TRANSCRIPTION FACTOR;

EID: 61349169659     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-08-0255     Document Type: Article

References (37)

1. Berchuck A, Iversen ES, Lancaster JM, et al. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res 2005;11:3686-96.
2. Spentzos D, Levine DA, Ramoni MF, et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 2004;22:4700-10.
3. Flanagan JR, Becker KG, Ennist DL, et al. Cloning of a negative transcription factor that binds to the upstream conserved region of Moloney murine leukemia virus. Mol Cell Biol 1992;12:38 -44.
4. Hariharan N, Kelley DE, Perry RP. Delta, a transcription factor that binds to downstream elements in several polymerase II promoters, is a functionally versatile zinc finger protein. Proc Natl Acad Sci U S A 1991;88:9799 -803.
5. Park K, Atchison ML. Isolation of a candidate repressor/activator, NF-E1 (YY- 1, δ), that binds to the immunoglobulin κ 3' enhancer and the immunoglobulin heavy-chain μ E1 site. Proc Natl Acad Sci U S A 1991;88:9804-8.
6. Shi Y, Seto E, Chang LS, Shenk T. Transcriptional repression by YY1, a human GLI-Kruppel-related protein, and relief of repression by adenovirus E1A protein. Cell 1991;67:377-88.
7. Pisaneschi G, Ceccotti S, Falchetti ML, Fiumicino S, Carnevali F, Beccari E. Characterization of FIII/YY1, a Xenopus laevis conserved zinc-finger protein binding to the first exon of L1 and L14 ribosomal protein genes. Biochem Biophys Res Commun 1994;205:1236-42.
8. Brown JL, Mucci D, Whiteley M, Dirksen ML, Kassis JA. The Drosophila Polycomb group gene pleiohomeotic encodes a DNA binding protein with homology to the transcription factor YY1. Mol Cell 1998;1:1057 -64.
9. Gordon S, Akopyan G, Garban H, Bonavida B. Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene 2006;25:1125 -42.
10. Affar el B, Gay F, Shi Y, et al. Essential dosage-dependent functions of the transcription factor yin yang 1 in late embryonic development and cell cycle progression. Mol Cell Biol 2006;26:3565-81.
11. Palko L, Bass HW, Beyrouthy MJ, Hurt MM. The Yin Yang-1 (YY1) protein undergoes a DNA-replication-associated switch in localization from the cytoplasm to the nucleus at the onset of S phase. J Cell Sci 2004;117:465 -76.
12. Schlisio S, Halperin T, Vidal M, Nevins JR. Interaction of YY1 with E2Fs, mediated by RYBP, provides a mechanism for specificity ofE2F function. EMBO J 2002;21:5775 -86.
13. Petkova V, Romanowski MJ, Sulijoadikusumo I, et al. Interaction between YY1 and the retinoblastoma protein. Regulation of cell cycle progression in differentiated cells. J Biol Chem 2001;276:7932-6.
14. Wang CC, Chen JJ, Yang PC. Multifunctional transcription factor YY1: a therapeutic target in human cancer? Expert Opin Ther Targets 2006;10:253-66.
15. 1/S transition and DNA replication. Cancer Cell 2003;3:311-6.
16. Bandera CA, Takahashi H, Behbakht K, et al. Deletion mapping of two potential chromosome 14 tumor suppressor gene loci in ovarian carcinoma. Cancer Res 1997;57:513-5.
17. Cliby W, Ritland S, Hartmann L, et al. Human epithelial ovarian cancer allelotype. Cancer Res 1993;53:2393-8.
18. Osborne RJ, Leech V. Polymerase chain reaction allelotyping of human ovarian cancer. Br J Cancer 1994;69:429 -38.
19. Matys V, Fricke E, Geffers R, et al. TRANSFAC: transcriptional regulation, from patterns to profiles. Nucleic Acids Res 2003;31:374-8.
20. Harris MA, Clark J, Ireland A, et al. The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res 2004;32:D258 -61.
21. Chang J, Nevins J. GATHER: a systems approach to interpreting genomic signatures. Bioinformatics 2006;22:2926 -33.
22. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353 -7.
23. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1 -6.
24. Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum- based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361:2099-106.
25. Scherf U, Ross DT, Waltham M, et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000;24:236 -44.
26. Ohtani K, Iwanaga R, Nakamura M, et al. Cell growth-regulated expression of mammalian MCM5 and MCM6 genes mediated by the transcription factor E2F. Oncogene 1999;18:2299-309.
27. Halperin R, Zehavi S, Dar P, et al. Clinical and molecular comparison between borderline serous ovarian tumors and advanced serous papillary ovarian carcinomas. Eur J Gynaecol Oncol 2001;22:292-6.
28. Moreno CS, Matyunina L, Dickerson EB, et al. Evidence that p53-mediated cell-cycle-arrest inhibits chemotherapeutic treatment of ovarian carcinomas. PLoS ONE 2007;2:e441.
29. Itamochi H, Kigawa J, Sugiyama T, Kikuchi Y, Suzuki M, Terakawa N. Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol 2002;100:281 -7.
30. Hartmann LC, Sebo TJ, Kamel NA, et al. Proliferating cell nuclear antigen in epithelial ovarian cancer: relation to results at second-look laparotomy and survival. Gynecol Oncol 1992;47:191 -5.
31. Russo AJ, Magro PG, Hu Z, et al. E2F-1 overexpression in U2OS cells increases cyclin B1 levels and cdc2 kinase activity and sensitizes cells to antimitotic agents. Cancer Res 2006;66:7253 -60.
32. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-65.
33. Honore S, Pasquier E, Braguer D. Understanding microtubule dynamics for improved cancer therapy. Cell Mol Life Sci 2005;62:3039 -56.
34. Karolchik D, Baertsch R, Diekhans M, et al. The UCSC Genome Browser Database. Nucleic Acids Res 2003;31:51 -4.
35. Pruitt KD, Tatusova T, Maglott DR. NCBI Reference Sequence (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins. Nucleic Acids Res 2005;33:D501 -4.
36. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998;95:14863-8.
37. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-50.